User:Ajeffs: Difference between revisions
From OpenWetWare
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| (38 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
Back to [[Eccles Lab]] | <!--Back to [[Eccles Lab]] | [[User:Ajeffs/Notebook | Notebook]] <html><a href="/wiki/User:Ajeffs/Notebook"><img src="/images/9/94/Report.png" border="0" /></a></html> | ||
--> | |||
<!--[[User:Ajeffs/Notebook | Notebook]] <html><a href="/wiki/User:Ajeffs/Notebook"><img src="/images/9/94/Report.png" border="0" /></a></html> | |||
--> | |||
<font size="4">Aaron Jeffs</font size> | <font size="4">Aaron Jeffs</font size> | ||
<font size="2" | <font size="2"> | ||
Department of Pathology<br> | Department of Pathology<br> | ||
Dunedin School of Medicine<br> | Dunedin School of Medicine<br> | ||
| Line 14: | Line 16: | ||
</font size> | </font size> | ||
== Research Interests == | == Research Interests == | ||
*Cancer genetics | *Cancer genetics | ||
*Oncogenomics | |||
*eResearch | |||
== Education== | == Education== | ||
*MSc Hons (Canterbury) | *PhD (Otago) 2001. | ||
* | *MSc Hons (Canterbury) 1994. | ||
==Publications== | |||
===Peer-reviewed=== | |||
*Campbell HG, Slatter TL, Jeffs A, Mehta R, Rubio C, Baird M, Braithwaite AW (2012). Does Δ133p53 isoform trigger inflammation and autoimmunity? Cell Cycle. 2012 Feb 1;11(3):446-50. Epub 2012 Feb 1. PMID: 22262184. | |||
*Slatter, T. L., Hung, N., ..., Renshaw, P., Williams, G., Wilson, M., Engelmann, A., Jeffs, A., Royds, J. A., Baird, M. A., & Braithwaite, A. W. (2011). Hyperproliferation, cancer, and inflammation in mice expressing a Δ133p53-like isoform.<i> Blood</i>,<i> 117</i>(19), 5166-5177. http://dx.doi.org/10.1182/blood-2010-11-321851. | |||
*Jeffs, A. R., Glover, A. C., Slobbe, L. J., Wang, L., He, S., Hazlett, J. A., Awasthi, A., Woolley, A. G., Marshall, E. S., Joseph, W. R., Print, C. G., Baguley, B. C., & Eccles, M. R. (2009). A gene expression signature of invasive potential in metastatic melanoma cells.<i> PLoS ONE</i>,<i> 4</i>(12), e8461. http://dx.doi.org/10.1371/journal.pone.0008461. | |||
*Jenkins, Z. A., van Kogelenberg, M., Morgan, T., Jeffs, A., Fukuzawa, R., Pearl, E., ..., & Robertson, S. P. (2009). Germline mutations in <i>WTX</i> cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis.<i> Nature Genetics</i>,<i> 41</i>(1), 95-100. http://dx.doi.org/10.1038/ng.270. | |||
*Dziarmaga, A., Hueber, P-A., Iglesias, D., Hache, N., Jeffs, A., Gendron, N., MacKenzie, A., Eccles, M., & Goodyer, P. (2006). Neuronal apoptosis inhibitory protein is expressed in developing kidney and is regulated by PAX2.<i> American Journal of Physiology - Renal Physiology</i>,<i> 291</i>, F913-F920. | |||
*Futschik, M., Jeffs, A. R., Pattison, S. T., Kasabov, N., Sullivan, M. J., Merrie, A. E. M., & Reeve, A. E. (2002). Gene expression profiling of metastatic and nonmetastatic colorectal cancer cell lines.<i> Genome Letters</i>,<i> 1</i>, 26-34. | |||
*Jeffs, A. R., Wells, J. E., & Morris, C. M. (2001). Nonrandom distribution of interspersed repeat elements in the BCR and ABL1 genes and its relation to breakpoint cluster regions.<i> Genes Chromosomes and Cancer</i>,<i> 32</i>(2), 144-154. | |||
*Benjes, S. M., Millow, L. J., Jeffs, A. R., Sowerby, S. J., Reeve, A. E., & Morris, C. M. (1999). 3'BCR recombines with IGL locus in BCR-ABL-positive Philadelphia-negative chronic myeloid leukaemia.<i> Genes Chromosomes Cancer</i>,<i> 26</i>, 366-371. | |||
*Jeffs, A. R., Benjes, S. M., Smith, T. L., Sowerby, S. J., & Morris, C. M. (1998). The BCR gene recombines preferentially with Alu elements in complex BCR-ABL translocations of chronic myeloid leukaemia.<i> Human Molecular Genetics</i>,<i> 7</i>, 767-776. | |||
*Morris, C. M., Jeffs, A. R. M., Smith, T. P. L., McDonald, M., Board, P., Kennedy, M. A., & Fitzgerald, P. H. (1996). BCR gene recombines with genomically distinct sites on band 11q13 in complex BCR-ABL translocations of chronic myeloid leukemia.<i> Oncogene</i>,<i> 12</i>, 677-685. | |||
===Non-peer-reviewed=== | |||
Robson, Ewan, Jeffs, Aaron, and Eccles, Michael. Off-target response to decoy oligodeoxynucleotide treatment. Available from Nature Precedings http://hdl.handle.net/10101/npre.2008.2281.1 (2008) | |||
<!-- ==Publications== | |||
===Peer-reviewed=== | |||
<biblio> | |||
#Campbell-2012 pmid=22262184 | |||
#Slatter-2010 pmid=21411755 | |||
#Jeffs-2009 pmid=20041153 | |||
#Jenkins-2008 pmid=19079258 | |||
#Dziarmaga-2006 pmid=16735463 | |||
#Futschik-2002 M. Futschik, A.Jeffs, S.Pattison, N.Kasabov, M.Sullivan, A.Merrie, A.Reeve (2002). ''Gene expression profiling of metastatic and non-metastatic colorectal cancer cell-lines''. Genome Letters 1(1):26-34. | |||
#Jeffs-2001 pmid=11550282 | |||
#Benjes-1999 pmid=10534772 | |||
#Jeffs-1998 pmid=9536079 | |||
#Morris-1996 pmid=8637725 | |||
</biblio> | |||
== | ===Non-peer-reviewed=== | ||
<biblio> | <biblio> | ||
# | #Robson-2008 Robson, Ewan, Jeffs, Aaron, and Eccles, Michael. Off-target response to decoy oligodeoxynucleotide treatment. Available from Nature Precedings http://hdl.handle.net/10101/npre.2008.2281.1 (2008) | ||
</biblio> | </biblio> | ||
--> | |||
==Funding== | |||
===2011=== | |||
*"p53 isoforms, miRNA, and cancer", Dunedin School of Medicine Dean's Bequest Round, 27 May 2011 for 1 year ($14,569). A. Jeffs and A. Braithwaite. | |||
===2010=== | |||
*"MicroRNA function in melanoma", The Healthcare Otago Charitable Trust, October 2010 for 1 year ($14,127). A. Jeffs. | |||
*"Urinary microRNA: a novel marker of acute kidney injury", University of Otago Research grant, October 2010 for 1 year ($44,000). R. Walker (PI), A. Jeffs, Z. Endre, and J. Pickering. | |||
*"Can isoforms of the p53 tumour suppressor cause cancer?", Health Research Council of New Zealand, June 2010 for 36 months ($1,158,492). A. Braithwaite (PI), N. Hung, A. Jeffs, and T. Slatter. | |||
*"A novel gene that modifies melanoma invasive potential", Dunedin School of Medicine Dean's Bequest Fund, June 2010 for 1 year ($5420). A. Jeffs. | |||
*"Grant-in-aid for QMB Cancer meeting 2010", Maurice & Phyllis Paykel Trust ($4000). A. Jeffs & M. Eccles. | |||
*Professional Development Award to attend the AMATA10 meeting, Hobart, Australia, Genesis Oncology Trust ($1,957). A. Jeffs. | |||
*Dunedin School of Medicine Travel Grant to attend the AMATA10 meeting, Hobart, Australia ($885). A.Jeffs. | |||
===2009=== | |||
*"Genome instability in melanoma", NZ Lottery Grants Board (Application 278243), 01/01/2010 for 2 years ($116,328). A. Jeffs (PI), M. Eccles, and B. Baguley. | |||
*"The molecular basis of melanoma: integrating microRNA expression and DNA copy number variation to define clinically relevant markers of invasion and prognosis", The HealthCare Otago Charitable Trust ($10,434), 01/02/10 for 1 year. A. Jeffs. | |||
<!--<html> | <!--<html> | ||
| Line 42: | Line 93: | ||
weekstart=7 | weekstart=7 | ||
</calendar> | </calendar> | ||
<html><iframe src="http://www.otago.ac.nz/researchpublications/?sPerName=Dr+Aaron+Jeffs&sAOUname=&sManage=&sDivisionName=&sCategory=D1&sType=&sPubTitle=&sPublisher=&sKeyword=&sPublicationyear_from=&sPublicationyear_to=&iResults=&sortResults=categoryyear&command=submit" style="width: 640px; height: 614px;"></iframe></html> | |||
--> | |||
Latest revision as of 23:39, 16 September 2012
Aaron Jeffs
Department of Pathology
Dunedin School of Medicine
University of Otago
Dunedin
New Zealand
aaron.jeffs at otago.ac.nz
Research Interests
- Cancer genetics
- Oncogenomics
- eResearch
Education
- PhD (Otago) 2001.
- MSc Hons (Canterbury) 1994.
Publications
Peer-reviewed
- Campbell HG, Slatter TL, Jeffs A, Mehta R, Rubio C, Baird M, Braithwaite AW (2012). Does Δ133p53 isoform trigger inflammation and autoimmunity? Cell Cycle. 2012 Feb 1;11(3):446-50. Epub 2012 Feb 1. PMID: 22262184.
- Slatter, T. L., Hung, N., ..., Renshaw, P., Williams, G., Wilson, M., Engelmann, A., Jeffs, A., Royds, J. A., Baird, M. A., & Braithwaite, A. W. (2011). Hyperproliferation, cancer, and inflammation in mice expressing a Δ133p53-like isoform. Blood, 117(19), 5166-5177. http://dx.doi.org/10.1182/blood-2010-11-321851.
- Jeffs, A. R., Glover, A. C., Slobbe, L. J., Wang, L., He, S., Hazlett, J. A., Awasthi, A., Woolley, A. G., Marshall, E. S., Joseph, W. R., Print, C. G., Baguley, B. C., & Eccles, M. R. (2009). A gene expression signature of invasive potential in metastatic melanoma cells. PLoS ONE, 4(12), e8461. http://dx.doi.org/10.1371/journal.pone.0008461.
- Jenkins, Z. A., van Kogelenberg, M., Morgan, T., Jeffs, A., Fukuzawa, R., Pearl, E., ..., & Robertson, S. P. (2009). Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis. Nature Genetics, 41(1), 95-100. http://dx.doi.org/10.1038/ng.270.
- Dziarmaga, A., Hueber, P-A., Iglesias, D., Hache, N., Jeffs, A., Gendron, N., MacKenzie, A., Eccles, M., & Goodyer, P. (2006). Neuronal apoptosis inhibitory protein is expressed in developing kidney and is regulated by PAX2. American Journal of Physiology - Renal Physiology, 291, F913-F920.
- Futschik, M., Jeffs, A. R., Pattison, S. T., Kasabov, N., Sullivan, M. J., Merrie, A. E. M., & Reeve, A. E. (2002). Gene expression profiling of metastatic and nonmetastatic colorectal cancer cell lines. Genome Letters, 1, 26-34.
- Jeffs, A. R., Wells, J. E., & Morris, C. M. (2001). Nonrandom distribution of interspersed repeat elements in the BCR and ABL1 genes and its relation to breakpoint cluster regions. Genes Chromosomes and Cancer, 32(2), 144-154.
- Benjes, S. M., Millow, L. J., Jeffs, A. R., Sowerby, S. J., Reeve, A. E., & Morris, C. M. (1999). 3'BCR recombines with IGL locus in BCR-ABL-positive Philadelphia-negative chronic myeloid leukaemia. Genes Chromosomes Cancer, 26, 366-371.
- Jeffs, A. R., Benjes, S. M., Smith, T. L., Sowerby, S. J., & Morris, C. M. (1998). The BCR gene recombines preferentially with Alu elements in complex BCR-ABL translocations of chronic myeloid leukaemia. Human Molecular Genetics, 7, 767-776.
- Morris, C. M., Jeffs, A. R. M., Smith, T. P. L., McDonald, M., Board, P., Kennedy, M. A., & Fitzgerald, P. H. (1996). BCR gene recombines with genomically distinct sites on band 11q13 in complex BCR-ABL translocations of chronic myeloid leukemia. Oncogene, 12, 677-685.
Non-peer-reviewed
Robson, Ewan, Jeffs, Aaron, and Eccles, Michael. Off-target response to decoy oligodeoxynucleotide treatment. Available from Nature Precedings http://hdl.handle.net/10101/npre.2008.2281.1 (2008)
Funding
2011
- "p53 isoforms, miRNA, and cancer", Dunedin School of Medicine Dean's Bequest Round, 27 May 2011 for 1 year ($14,569). A. Jeffs and A. Braithwaite.
2010
- "MicroRNA function in melanoma", The Healthcare Otago Charitable Trust, October 2010 for 1 year ($14,127). A. Jeffs.
- "Urinary microRNA: a novel marker of acute kidney injury", University of Otago Research grant, October 2010 for 1 year ($44,000). R. Walker (PI), A. Jeffs, Z. Endre, and J. Pickering.
- "Can isoforms of the p53 tumour suppressor cause cancer?", Health Research Council of New Zealand, June 2010 for 36 months ($1,158,492). A. Braithwaite (PI), N. Hung, A. Jeffs, and T. Slatter.
- "A novel gene that modifies melanoma invasive potential", Dunedin School of Medicine Dean's Bequest Fund, June 2010 for 1 year ($5420). A. Jeffs.
- "Grant-in-aid for QMB Cancer meeting 2010", Maurice & Phyllis Paykel Trust ($4000). A. Jeffs & M. Eccles.
- Professional Development Award to attend the AMATA10 meeting, Hobart, Australia, Genesis Oncology Trust ($1,957). A. Jeffs.
- Dunedin School of Medicine Travel Grant to attend the AMATA10 meeting, Hobart, Australia ($885). A.Jeffs.
2009
- "Genome instability in melanoma", NZ Lottery Grants Board (Application 278243), 01/01/2010 for 2 years ($116,328). A. Jeffs (PI), M. Eccles, and B. Baguley.
- "The molecular basis of melanoma: integrating microRNA expression and DNA copy number variation to define clinically relevant markers of invasion and prognosis", The HealthCare Otago Charitable Trust ($10,434), 01/02/10 for 1 year. A. Jeffs.
